Novo Nordisk A/S (NYSE:NVO) Shares Acquired by RWA Wealth Partners LLC

RWA Wealth Partners LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 48.8% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 90,823 shares of the company’s stock after purchasing an additional 29,787 shares during the period. RWA Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $7,813,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Intrust Bank NA increased its holdings in Novo Nordisk A/S by 3.3% during the 4th quarter. Intrust Bank NA now owns 8,717 shares of the company’s stock worth $750,000 after purchasing an additional 281 shares during the period. Brown Brothers Harriman & Co. raised its holdings in Novo Nordisk A/S by 60.9% in the fourth quarter. Brown Brothers Harriman & Co. now owns 60,121 shares of the company’s stock valued at $5,172,000 after acquiring an additional 22,754 shares in the last quarter. Horizon Investment Services LLC lifted its stake in Novo Nordisk A/S by 26.0% in the fourth quarter. Horizon Investment Services LLC now owns 3,699 shares of the company’s stock worth $318,000 after acquiring an additional 764 shares during the last quarter. Orion Portfolio Solutions LLC grew its holdings in Novo Nordisk A/S by 10.5% during the 4th quarter. Orion Portfolio Solutions LLC now owns 297,996 shares of the company’s stock worth $25,634,000 after acquiring an additional 28,331 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. increased its position in shares of Novo Nordisk A/S by 113.1% in the 4th quarter. Nomura Asset Management Co. Ltd. now owns 43,776 shares of the company’s stock valued at $3,766,000 after purchasing an additional 23,238 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 1.1 %

NVO stock opened at $69.36 on Friday. Novo Nordisk A/S has a 12 month low of $69.18 and a 12 month high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The company has a market cap of $311.23 billion, a price-to-earnings ratio of 21.08, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. The company has a fifty day moving average price of $82.33 and a 200 day moving average price of $98.89.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a dividend of $0.7874 per share. The ex-dividend date is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 47.72%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on NVO shares. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Stifel Nicolaus downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.